For the year ending 2025-12-31, CYTK had $30,400K increase in cash & cash equivalents over the period. -$534,816K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -784,955 |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreement | 58,367 |
| Stock-based compensation expense | 112,286 |
| Non-cash lease expense | 5,648 |
| Loss on disposition of property and equipment | 0 |
| Depreciation of property and equipment | 10,125 |
| Change in fair value of derivative liabilities | 4,200 |
| Change in fair value of liabilities related to rpi transactions | -200 |
| Realized (loss) gain on investment, net | 25 |
| Interest receivable and amortization on investments | -15,977 |
| Non-cash interest expense related to debt | 22,901 |
| Debt conversion expense | 121,249 |
| Accounts receivable | 1,114 |
| Prepaid and other assets | 2,933 |
| Accounts payable | 2,663 |
| Deferred revenue | -50,758 |
| Accrued and other liabilities | 33,603 |
| Operating lease liabilities | -10,839 |
| Other non-current liabilities | -6,250 |
| Net cash used in operating activities | -510,009 |
| Purchases of investments | 1,063,173 |
| Investment in non-marketable equity security | 5,000 |
| Maturities of investments | 1,103,645 |
| Sales of investments | 6,001 |
| Purchases of property and equipment | 24,807 |
| Net cash (used in) provided by investing activities | 16,666 |
| Repayment of finance lease liabilities | 204 |
| Repayment of term loan | 10,809 |
| Repayment of convertible debt | 402,500 |
| Proceeds from issuance of convertible debt, net | 729,460 |
| Proceeds from draw on rpi multi tranche loan | 175,000 |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs-At The Market Offering | 0 |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs-Public Offering | 0 |
| Proceeds from issuance of common stock related to private placement, net of issuance costs | 0 |
| Proceeds from issuance of common stock under equity incentive and stock purchase plans | 35,979 |
| Taxes paid related to net share settlement of equity awards | 2,468 |
| Net cash provided by financing activities | 524,458 |
| Effect of exchange rate changes | -715 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 30,400 |
| Cash, cash equivalents, and restricted cash, beginning of period | 95,232 |
| Cash, cash equivalents, and restricted cash, end of period | 125,632 |
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)